TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07503444: A Phase 3 Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study With Open-Label Extension to Evaluate the Efficacy And Safety of Fenfluramine Hydrochloride in Study Participants With Rett Syndro

Sponsor: UCB BIOSCIENCES, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$8,485,920

Rescue Site Savings

+$5,610,136

Unlock Full NCT07503444 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07503444 Rescue Dossier →